Funded Biomarker Testing
5 items
Promoter Methylation testing should be performed for all MMR cases with abnormal MLH1 results*.
Funded Biomarker Disease Site: Adrenal Gland, Bladder/ Urothelial, Colorectal, Endometrium, Esophagus, Hepatobiliary, Ocular, Ovary, Pancreas, Skin, Small Bowel, Stomach
Biomarker: MLH1 Methylation
Testing Method:Methylation
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, Trillium Health Partners, University Health Network
Reflex testing on newly diagnosed tumours with invasive endometrial cancer.
Funded Biomarker Disease Site: Endometrium
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with invasive endometrial carcinoma.
Funded Biomarker Disease Site: Endometrium
Biomarker: POLE, CTNNB1, KRAS, PIK3CA, PTEN, TP53
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with invasive endometrial carcinoma when needed to establish subtype.
Funded Biomarker Disease Site: Endometrium
Biomarker: P53, PR, ER
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Serous (high grade/advanced) endometrial carcinoma where HER2 directed therapy is being considered.
Funded Biomarker Disease Site: Endometrium
Biomarker: HER2
Testing Method:In Situ Hybridization (ISH)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System